Ackman's Latest Remarks Level Valeant Pharmaceuticals Intl Inc (VRX)

Valeant Pharmaceuticals Intl Inc's (VRX) positive momentum has stalled, after Bill Ackman said the drugmaker won't be selling Bausch & Lomb

by Alex Eppstein

Published on Apr 8, 2016 at 11:59 AM

After a couple days of strong gains, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has resumed its longer-term trend lower. The losses come after activist investor and VRX board member Bill Ackman said the drugmaker will not be selling its core Bausch & Lomb unit, but only non-core assets. Suffice it to say, bullish options traders can't be very happy with today's stock performance.

Specifically, VRX has shed 5.8% at $33.46, succumbing to pressure from its descending 20-day moving average. Longer term, the stock has plummeted 87% since its all-time high of $263.81 in early August amid a series of scandals, a number of which have been related to the drugmaker's questionable pricing practices.

As alluded to, options traders have taken a glass-half-full approach toward VRX, buying to open nearly twice as many calls as puts during the last two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The resultant call/put volume ratio of 1.90 outstrips nearly four-fifths of readings from the past year, confirming the bullish bias.

Analysts, on the other hand, are anything but sold on Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Over two-thirds of brokerage firms consider the stock a "hold" or worse. On a related note, market pundit Jim Cramer said yesterday VRX has a number of considerations working in its favor -- including Ackman's support -- but warned investors to be cautious due to the drugmaker's $30 billion debt load and bleak sales outlook.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Google Postpones Android Reveal, "Now is Not the Time to Celebrate"
"Now is not the time to celebrate," Google said in a message on its website
ZNGA Zooms to 8-Year High on Billion-Dollar Deal
ZNGA is planning to buy Peak for $1.8 billion
Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....